Welcome to our dedicated page for Baird Medical Investment Holdings SEC filings (Ticker: BDMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baird Medical Investment Holdings Ltd. filings document foreign-issuer current reports for a microwave ablation medical device company. The disclosed records include Form 6-K reporting on auditor changes, board and audit committee actions, and financial-reporting controls.
The company's SEC disclosures also address accounting and reporting matters relevant to its Form 20-F status, including U.S. GAAP and SEC reporting requirements, independent registered public accounting firm appointments, and disclosed material weaknesses in internal control over financial reporting.
Baird Medical Investment Holdings Ltd director and 10% owner Wu Haimei has reported a direct holding of 18,195,281 Ordinary Shares of BDMD. The Form 3 entry reflects this ownership position, with no associated buy or sell transactions indicated in the data provided.
Baird Medical Investment Holdings Limited reported a change in its independent auditor. The company dismissed Kreit & Chiu CPA LLP and appointed Guangdong Prouden CPAs GP as its new independent registered public accounting firm, effective February 10, 2026, for the year ended December 31, 2025.
Kreit & Chiu’s prior reports for the year ended December 31, 2024 contained no adverse opinions or qualifications, and the company states there were no disagreements on accounting, disclosure, or audit scope. However, the company continues to have material weaknesses in internal control over financial reporting, including insufficient U.S. GAAP/SEC-experienced staff and the absence of a comprehensive U.S. GAAP accounting policy manual and documented controls. The new auditor is aware these material weaknesses are considered a reportable event.
Baird Medical Investment Holdings Limited has filed a prospectus to register up to 11,500,000 ordinary shares issuable upon exercise of public warrants at US$11.50 per share, plus up to 34,415,562 ordinary shares for resale by existing shareholders, including Betters Medical shareholders, the SPAC sponsor, Cohen, Grand Fortune Capital and its Hong Kong affiliate.
The company will not receive proceeds from resale of these 34,415,562 shares and expects limited cash from warrant exercises because its Nasdaq share price of US$1.63 on December 4, 2025 was well below the US$11.50 exercise price. The filing notes that, assuming warrant exercise and preferred share conversion, these resale shares represent about 70.9% of shares outstanding, and large sales could pressure the stock price. Baird Medical operates through PRC subsidiaries, highlights significant regulatory and capital-flow risks tied to China, and warns that HFCAA-related auditor inspection issues could eventually lead to a Nasdaq delisting, which could cause the ordinary shares’ value to decline substantially.